SCHEMBL454669

SCHEMBL454669

CC(C)(C)OC(=O)c1cc(-c2ccc(F)cc2)c2nnc(-c3ccccn3)n2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SQOR Q9Y6N5 3/20 0.41
TACR3 P29371 5/20 0.40
ALDH1A1 P00352 2/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
MAPT P10636 1/20 0.40
DCTPP1 Q9H773 1/20 0.39
SYK P43405 1/20 0.39
MAPK1 P28482 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
TUBB4A P04350 1/20 0.37
TUBB P07437 1/20 0.37
TUBA3C P0DPH7 1/20 0.37
TUBA1B P68363 1/20 0.37
TUBA4A P68366 1/20 0.37
TUBB4B P68371 1/20 0.37
TUBB3 Q13509 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL451880 0.85 TACR3 (0.45) SQORTACR3ALDH1A1NPC1RAB9A
SCHEMBL452183 0.82 TACR3 (0.40) TACR3ALDH1A1NPC1RAB9AMAPT
SCHEMBL455880 0.79 BRD9 (0.38) ALDH1A1NPC1RAB9AMAPTTUBB4A
SCHEMBL451640 0.72 DGAT2 (0.48) TACR3CYP2C9
SCHEMBL454107 0.69 BRD9 (0.40) ALDH1A1MAPTCYP1A2CYP2C9CYP2C19
SCHEMBL20620216 0.66 KDM4E (0.49) SQORNPC1MAPK1CYP1A2L3MBTL1
SCHEMBL20620218 0.66 KDM4E (0.60) NPC1CYP1A2SMN1; SMN2
SCHEMBL23550669 0.65 L3MBTL1 (0.37) ALDH1A1NPC1RAB9AMAPTL3MBTL1
SCHEMBL452133 0.65 CA12 (0.34) ALDH1A1MAPTMAPK1CYP1A2L3MBTL1
SCHEMBL22844250 0.64 KDM4C (0.42)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9238647-B2 P2X3 receptor antagonists for treatment of pain MERCK SHARP & DOHME CORP. (US) 2016-01-19 US disclosed
EP-2410857-B1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK SHARP & DOHME (US) 2014-01-29 EP disclosed
US-20120064181-A1 P2X3 Receptor Antagonists for Treatment of Pain MERCK SHARP & DOHME LLC 2012-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120064181-A1 P2X3 Receptor Antagonists for Treatment of Pain P2RX3, P2RX1, P2RX2 SQOR 3061/4885TACR3 87/4885ALDH1A1 2538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.